塞来昔布对重型颅脑损伤患者临床疗效及神经功能的影响

发布时间：2018-01-31 09:29

本文关键词： 塞来昔布重型颅脑损伤神经功能临床疗效　出处：《中国医院药学杂志》2017年24期 　论文类型：期刊论文

【摘要】：目的:探讨塞来昔布对重型颅脑损伤患者临床疗效及神经功能的影响。方法:选取某院2014年1月-2016年12月重型颅脑损伤患者80例,并将其分为治疗组和对照组。对照组进行常规治疗,治疗组在对照组的基础上给予塞来昔布治疗。检测2组患者血清TNF-α、IL-1β水平变化。2组患者治疗7 d、14 d后行GCS评分,3个月后按GOS预后评分评定预后,治疗前及治疗3个月后Barthel指数评分,治疗期间清醒时间及意识恢复清醒情况。结果:治疗组患者治疗后IL-1β、TNF-α水平显著低于治疗前(P0.05);治疗组患者治疗7 d、14 d后GCS评分均较治疗前明显增高(P0.05),治疗组患者治疗结束及随访结束时GOS评分均明显高于对照组(P0.05);治疗组患者治疗3个月后Barthel评分相较对照组显著提高(P0.05);治疗组患者治疗期间清醒时间明显长于对照组(P0.05);治疗组患者治疗期间意识恢复率明显高于对照组(P0.05);治疗组患者治愈率较对照组显著升高(P0.05),治疗组患者重残率与病死率较对照组显著降低(P0.05)。结论:塞来昔布可改善重型颅脑损伤患者预后及日常生活能力,促进神经功能恢复、降低病死率,临床疗效确切。
[Abstract]:Objective: to investigate the effect of celecoxib on the clinical efficacy and neurological function of patients with severe craniocerebral injury. Methods: 80 patients with severe craniocerebral injury from January 2014 to December 2016 in a hospital were selected. The patients in the treatment group were treated with celecoxib on the basis of the control group, and the serum TNF- 伪 was detected in the two groups. The changes of IL-1 尾 level in group 2 were evaluated by GCS score after 7 days and 14 days after treatment. The prognosis was evaluated by GOS prognostic score 3 months later. Barthel index score before treatment and 3 months after treatment, waking time and consciousness recovery during treatment. Results: IL-1 尾 in the treatment group after treatment. The level of TNF- 伪 was significantly lower than that before treatment (P 0.05). The GCS scores of the patients in the treatment group were significantly higher than those before treatment (P0.05). The GOS score at the end of treatment and follow-up in the treatment group was significantly higher than that in the control group (P 0.05). After 3 months of treatment, the Barthel score of the patients in the treatment group was significantly higher than that in the control group (P 0.05). The waking time of the patients in the treatment group was longer than that in the control group (P 0.05). The recovery rate of consciousness in the treatment group was significantly higher than that in the control group (P 0.05). The cure rate in the treatment group was significantly higher than that in the control group (P0.05). Conclusion: celecoxib can improve the prognosis and daily life ability of patients with severe craniocerebral injury and promote the recovery of nerve function. To reduce the mortality rate, the clinical curative effect is definite.
【作者单位】：河北医科大学附属邢台市人民医院神经外科;邢台医学高等专科学校药学系;
【基金】：河北省自然科学基金项目(编号:C2004000689) 河北省博士基金项目(编号:05547008D-4) 河北省科学技术与社会发展计划项目(编号:04276135)
【分类号】：R651.15
【正文快照】： 颅脑外伤是神经外科常见一种急危重症,颅脑外伤的患病率占全身外伤性疾病的10%~15%,其中重型颅脑损伤(severe traumatic brain injury,sT-BI)病死率可高达30%~58%,其以病情重、病情复杂多变、并发症多、疗效差、治疗难度大、致残率和致死率高为特点[1]。常规治疗方法效果欠佳,

【相似文献】